

REMARKS

By this amendment, claims 12-28 have been canceled, claims 9-11 and 32-34 have been amended and new claims 35-40 have been added, without prejudice or disclaimer of any previously claimed subject matter. Support for the amendments and new claims can be found throughout the specification and in originally filed claims, for example claims 9-11.

With respect to all amendments and cancelled claims, Applicants have not dedicated or abandoned any unclaimed subject matter. Applicants expressly reserve the right to pursue prosecution of any presently excluded subject matter or claim embodiments in one or more future continuation and/or divisional application(s).


Applicants respectfully request entry of this submission and believe that the present application is now in condition for allowance. The Examiner is encouraged to call the undersigned to discuss any issues related to the prosecution of the instant application.

No additional fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535 referencing Docket No. 0302-UTL2-0. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Date: April 17, 2006

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.



Karen R. Zachow, Ph.D.

Reg. No. 46,332

Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, California 92121
Phone (858) 552-2200
Facsimile (858) 552-1936